Oxford Immunotec announces US FDA approval of PMA supplement for the use of the T-Cell Xtend® reagent Independent study demonstrates that T-SPOT®.TB assay outperforms TST in predicting TB disease The T-SPOT®.TB Test Now Included in New CDC Guidelines Oxford Immunotec Closes Second Tranche of $26 Million Series D Financing Led by New Leaf Venture Partners New study confirms 98.9% specificity of the T-SPOT®.TB assay Oxford Immunotec announces contract with Scancell Ltd to measure T cell 2010 World TB Day Oxford Immunotec Strengthens Leadership Team T-SPOT.TB is first IGRA to be Approved for Sale in Taiwan Oxford Immunotec Announces Board Changes T-SPOT ®.TB Gains FDA Premarket Approval Study Results Confirm T-SPOT®.TB Performance is not Affected by Low CD4 Count in HIV Infected Subjects Study Results Demonstrate Ability of T-SPOT®.TB to Monitor Declining Response in Subjects Receiving Anti-TB Treatment Oxford Immunotec Completes $40M Financing Study Results Confirm T-SPOT®.TB is Cost-Effective in TB Control Programmes 39 Articles